|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's range||13.73 - 14.49|
|52-week range||5.00 - 15.59|
|PE ratio (TTM)||N/A|
|Earnings date||8 Aug 2018 - 13 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||22.00|
Achaogen (AKAO), a late-stage biopharmaceutical company, develops and commercializes antibacterial treatments for MDR (multidrug-resistant) gram-negative infections. Its lead product candidate, plazomicin, targets serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, which was identified as a “nightmare bacteria” by the Centers for Disease Control and Prevention in 2013. Of the 12 analysts covering Achaogen in April 2018, five have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “sell.” The mean rating for the stock is 1.8, and its target price is $21.56.
CymaBay Therapeutics’ (CBAY) MBX-2982 is under evaluation as a novel therapeutic agent. The company has yet to disclose its target indication. The drug was synthesized as a GPR119 agonist and is shown to increase glucose-dependent insulin secretion in animal models and in vitro. Non-clinical studies have shown MBX-2982 to have desirable effects on blood glucose levels.
CymaBay Therapeutics’ (CBAY) second product candidate, arhalofenate, is being developed for the treatment of gout. The drug has been studied in five phase two clinical trials in patients suffering from gout and has consistently demonstrated reduction of gout flares and serum uric acid (or sUA). Gout flares are recurring and painful episodes of joint inflammation.
CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.
CymaBay Therapeutics (CBAY) is currently developing seladelpar for treating primary biliary cholangitis (or PBC), which is an autoimmune disease that causes progressive destruction of the bile ducts in the liver. The company also plans to develop seladelpar for treating non-alcoholic steatohepatitis (or NASH). NASH is a serious chronic liver disease caused by excessive fat accumulation in the liver, which results in inflammation and cellular injury that can progress to fibrosis and cirrhosis and potentially liver failure.
CymaBay launched to a month-high Wednesday after unveiling strong data for a liver disease treatment — to the detriment of Intercept which has struggled with its rival drug.